AR008531A1 - Análogos a heptapeptidos antagonistas de la oxitocina - Google Patents
Análogos a heptapeptidos antagonistas de la oxitocinaInfo
- Publication number
- AR008531A1 AR008531A1 ARP970105543A ARP970105543A AR008531A1 AR 008531 A1 AR008531 A1 AR 008531A1 AR P970105543 A ARP970105543 A AR P970105543A AR P970105543 A ARP970105543 A AR P970105543A AR 008531 A1 AR008531 A1 AR 008531A1
- Authority
- AR
- Argentina
- Prior art keywords
- heptapeptides
- nucleus
- oxytocine
- antagonist
- analogs
- Prior art date
Links
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- -1 aromatic D-alpha-amino acid Chemical class 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 abstract 1
- 101800000989 Oxytocin Proteins 0.000 abstract 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 abstract 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229960001723 oxytocin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Los heptapéptidos análogos o sales farmacéuticamente aceptables de los mismos consisten en un nucleo hexapeptídico con un nitrogeno terminal S y unbeta-aminoalcohol con un carbono terminal Z unido al nucleo S por medio de una union amida, en el queel beta-aminoalcohol Z es -NR-CH(Q)-CH2-OH, donde Qrepresenta -(CH2)n-NH-A, donde n es 1-6 y A representa un H o -C(=NH)NH2, y R representa CH3 o C2H5, y el nucleo S es como se ve en la formula (1), donde X representa un D-alfa-aminoácido aromáticoe Y representa un alfa-aminoácido alifático, y posee una actividad antagonista a la oxitocina. También serevela: un método para su síntesis; composiciones farmacéuticas conteniendo estos análogos; la síntesis de dichas composiciones; un método decontrol decontracciones uterinas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9604341A SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Hepta-peptide oxytocin analogue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008531A1 true AR008531A1 (es) | 2000-01-19 |
Family
ID=20404757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970105543A AR008531A1 (es) | 1996-11-26 | 1997-11-26 | Análogos a heptapeptidos antagonistas de la oxitocina |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6143722A (es) |
| EP (1) | EP0938496B1 (es) |
| JP (1) | JP3405460B2 (es) |
| KR (1) | KR100463132B1 (es) |
| CN (1) | CN1129606C (es) |
| AR (1) | AR008531A1 (es) |
| AT (1) | ATE242264T1 (es) |
| AU (1) | AU713424B2 (es) |
| BR (1) | BR9713366B1 (es) |
| CA (1) | CA2272990C (es) |
| CZ (1) | CZ299532B6 (es) |
| DE (1) | DE69722651T2 (es) |
| DK (1) | DK0938496T3 (es) |
| EE (1) | EE03832B1 (es) |
| ES (1) | ES2203823T3 (es) |
| HR (1) | HRP970630B1 (es) |
| HU (1) | HU228568B1 (es) |
| IL (1) | IL129519A (es) |
| LT (1) | LT4650B (es) |
| LV (1) | LV12350B (es) |
| MY (1) | MY125555A (es) |
| NO (1) | NO321380B1 (es) |
| NZ (1) | NZ336445A (es) |
| PL (1) | PL189292B1 (es) |
| PT (1) | PT938496E (es) |
| RO (1) | RO120772B1 (es) |
| RU (1) | RU2180668C2 (es) |
| SE (1) | SE9604341D0 (es) |
| SI (1) | SI20026B (es) |
| SK (1) | SK283800B6 (es) |
| TR (1) | TR199901028T2 (es) |
| UA (1) | UA54459C2 (es) |
| WO (1) | WO1998023636A1 (es) |
| ZA (1) | ZA9710518B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| US6476072B1 (en) * | 2000-11-21 | 2002-11-05 | Arthur Vanmoor | Method of treating menstrual pain by enhancing the effectiveness of the human immune system |
| AU2003211011A1 (en) * | 2002-02-27 | 2003-09-09 | Ferring Bv | Intermediates and methods for making heptapeptide oxytocin analogues |
| WO2003093816A2 (en) * | 2002-05-02 | 2003-11-13 | Bayer Healtchare Ag | Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| UA76639C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| ATE301990T1 (de) * | 2003-07-25 | 2005-09-15 | Ferring Bv | Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung |
| ES2260563T3 (es) * | 2003-11-13 | 2006-11-01 | Ferring B.V. | Paquete de blister y forma farmaceutica solida para ello. |
| EP1555029A1 (en) | 2004-01-19 | 2005-07-20 | Ferring B.V. | Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension |
| US20060171909A1 (en) * | 2005-02-03 | 2006-08-03 | The Procter & Gamble Company | Cosmetic compositions comprising colorants with low free dye |
| SE0600482L (sv) * | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
| CA2988753A1 (en) | 2007-08-06 | 2009-02-12 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
| NZ587817A (en) * | 2008-03-31 | 2012-05-25 | Ferring Bv | Oxytocin analogues |
| LT3085381T (lt) | 2008-05-21 | 2018-06-11 | Ferring B.V. | Burnoje disperguojamas desmopresinas, skirtas naktinio šlapinimosi netrikdomo miego periodo pailginimui |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| WO2012007845A2 (en) | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| DK2684888T3 (da) | 2011-03-09 | 2019-08-19 | Jitsubo Co Ltd | Nye tværbundne peptider indeholdende ikke-peptid-tværbundet struktur, fremgangsmåde til syntetisering af tværbundne peptider og ny organisk forbindelse anvendt i fremgangsmåden |
| CN102875650B (zh) * | 2012-09-26 | 2014-06-11 | 深圳翰宇药业股份有限公司 | 巴卢西班的制备方法 |
| US9365615B2 (en) | 2013-09-09 | 2016-06-14 | Jitsubo Co., Ltd. | Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method |
| PL3037101T3 (pl) * | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
| US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| WO2017060339A1 (en) | 2015-10-06 | 2017-04-13 | Ferring B.V. | New methods for making barusiban and its intermediates |
| CA3009576A1 (en) | 2016-01-04 | 2017-07-13 | Merck Serono S.A. | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| WO2018015497A2 (en) | 2016-07-21 | 2018-01-25 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| CN114667141A (zh) | 2019-09-03 | 2022-06-24 | 奥布赛瓦股份公司 | 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案 |
| WO2021160597A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL155712B1 (en) * | 1987-12-21 | 1991-12-31 | Sandoz Ag | Method of obtaining novel crystalline form of cyclosporin |
| US5373089A (en) * | 1988-09-02 | 1994-12-13 | Northwestern University | Oxytocin antagonist |
| CA2036973A1 (en) * | 1990-02-27 | 1991-08-28 | Mark G. Bock | Cyclic hexapeptide oxytocin antagonists |
| SE9002384D0 (sv) * | 1990-07-09 | 1990-07-09 | Ferring Ab | Derivat av baklobshormoner |
| DE4022247A1 (de) * | 1990-07-12 | 1992-01-16 | Hoechst Ag | Verfahren zur extraktiven abtrennung von 2-alkylthio-5-phenylpyrimidinen aus ihren reaktionsgemischen |
| SE501678C2 (sv) * | 1993-07-13 | 1995-04-10 | Ferring Bv | Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid |
| SE523819C2 (sv) | 1994-01-27 | 2004-05-18 | Per-Ingvar Nilsson | Accelerationsmunstycke samt metod för dess användning |
| SE9400918L (sv) | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| SE503085C2 (sv) | 1995-01-25 | 1996-03-25 | Valeo Engine Cooling Ab | Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan |
-
1996
- 1996-11-26 SE SE9604341A patent/SE9604341D0/xx unknown
-
1997
- 1997-11-21 DK DK97946210T patent/DK0938496T3/da active
- 1997-11-21 DE DE69722651T patent/DE69722651T2/de not_active Expired - Lifetime
- 1997-11-21 PT PT97946210T patent/PT938496E/pt unknown
- 1997-11-21 RO RO99-00593A patent/RO120772B1/ro unknown
- 1997-11-21 JP JP52460298A patent/JP3405460B2/ja not_active Expired - Lifetime
- 1997-11-21 TR TR1999/01028T patent/TR199901028T2/xx unknown
- 1997-11-21 AT AT97946210T patent/ATE242264T1/de active
- 1997-11-21 HU HU0000577A patent/HU228568B1/hu unknown
- 1997-11-21 AU AU51429/98A patent/AU713424B2/en not_active Expired
- 1997-11-21 WO PCT/SE1997/001968 patent/WO1998023636A1/en not_active Ceased
- 1997-11-21 ZA ZA9710518A patent/ZA9710518B/xx unknown
- 1997-11-21 CA CA002272990A patent/CA2272990C/en not_active Expired - Lifetime
- 1997-11-21 EE EEP199900210A patent/EE03832B1/xx unknown
- 1997-11-21 CZ CZ0183299A patent/CZ299532B6/cs not_active IP Right Cessation
- 1997-11-21 HR HR970630A patent/HRP970630B1/xx not_active IP Right Cessation
- 1997-11-21 IL IL12951997A patent/IL129519A/en not_active IP Right Cessation
- 1997-11-21 US US09/308,912 patent/US6143722A/en not_active Expired - Lifetime
- 1997-11-21 CN CN97180014A patent/CN1129606C/zh not_active Expired - Fee Related
- 1997-11-21 UA UA99042410A patent/UA54459C2/uk unknown
- 1997-11-21 SK SK704-99A patent/SK283800B6/sk not_active IP Right Cessation
- 1997-11-21 ES ES97946210T patent/ES2203823T3/es not_active Expired - Lifetime
- 1997-11-21 PL PL97333876A patent/PL189292B1/pl unknown
- 1997-11-21 KR KR10-1999-7004449A patent/KR100463132B1/ko not_active Expired - Lifetime
- 1997-11-21 SI SI9720076A patent/SI20026B/sl unknown
- 1997-11-21 RU RU99113364/04A patent/RU2180668C2/ru active
- 1997-11-21 BR BRPI9713366-3A patent/BR9713366B1/pt not_active IP Right Cessation
- 1997-11-21 NZ NZ336445A patent/NZ336445A/en not_active IP Right Cessation
- 1997-11-21 EP EP97946210A patent/EP0938496B1/en not_active Expired - Lifetime
- 1997-11-25 MY MYPI97005691A patent/MY125555A/en unknown
- 1997-11-26 AR ARP970105543A patent/AR008531A1/es active IP Right Grant
-
1999
- 1999-04-30 LV LVP-99-77A patent/LV12350B/en unknown
- 1999-05-11 LT LT99-052A patent/LT4650B/lt not_active IP Right Cessation
- 1999-05-26 NO NO19992532A patent/NO321380B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008531A1 (es) | Análogos a heptapeptidos antagonistas de la oxitocina | |
| AU673398B2 (en) | Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
| ES8604111A1 (es) | Procedimiento para preparar el compuesto 3-amino-3-deoxi-es-tanina | |
| KR880003974A (ko) | 디아민의 선택적 아미딘화 방법 | |
| DK0889877T3 (da) | Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer | |
| ES2067456T3 (es) | Nuevos derivados de aminoacidos, procedimientos para su preparacion y composicion farmaceutica que los comprende. | |
| ES2179318T3 (es) | Derivados de acido cinamico y su uso como antagonistas de integrina. | |
| LV5794A4 (lv) | Nonapeptidi ar bombezina antagonistu ipasibam | |
| ES2015645A6 (es) | Procedimiento de obtencion de un peptido de calcitonina o antagonista de la hormona liberadora de hormona luteinizante. | |
| ES2127524T3 (es) | Derivados de benzamida como antagonistas de vasopresina. | |
| EA200000804A1 (ru) | Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина | |
| AU2005265164A2 (en) | Non-natural amino acids | |
| ES8800158A1 (es) | Un procedimiento para la preparacion de derivados monoamidicos de etilendiamina | |
| AR008621A1 (es) | Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto | |
| IT1244501B (it) | Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono | |
| GB1176173A (en) | Novel Fluorene Compounds | |
| HRP20031055B1 (hr) | Novi imunomodulirajući spojevi | |
| ES2077878T3 (es) | Derivados substituidos de amidas de aminoacidos, su obtencion y su empleo como fungicidas. | |
| ES515722A0 (es) | Procedimientos para preparar derivados de tretalina. | |
| ES8707550A1 (es) | Un procedimiento para preparar compuestos peptidicos sustituidos. | |
| AR027454A1 (es) | Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos | |
| DeVita et al. | Benzolactam growth hormone secretagogues: Carboxamides as replacements for the 2′-tetrazole moiety of L-692,429 | |
| SE8501988D0 (sv) | Iminothiazolidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |